Potential public health impact of a Neisseria meningitidis A, B, C, W, and Y pentavalent vaccine in the United States

References

• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(suppl 2):S3–S11.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 suppl):S12–20.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018 [Internet]. 2019 [cited 2020 Jul 2]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf
   Google Scholar
• Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP) [Internet]. MMWR Recomm Rep. 2013 Mar 22 [[cited 2020 Jul 2]]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–1176.
   PubMed Web of Science ®Google Scholar
• Ahmed F, Centers for Disease Control and Prevention. U.S. Advisory Committee on Immunization Practices (ACIP) handbook for developing evidence-based recommendations. Version 1.2 [Internet]. 2013 November 1 [cited 2020 Jul 2]. Available from: http://www.cdc.gov/vaccines/acip/recs/GRADE/downloads/handbook.pdf.
   Google Scholar
• Advisory Committee on Immunization Practices. Summary report, June 26-27, 2019 [Internet]. 2019 [cited 2020 Jul 2]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2019-06-508.pdf
   Google Scholar
• Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718–723.
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. Summary report, February 27-28, 2019 [Internet]. 2019 February 27-28 [cited 2020 Jul 2]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2019-02-508.pdf
   Google Scholar
• Happe LE, Lunacsek OE, Marshall GS, et al. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13(9):506–512.
   PubMed Web of Science ®Google Scholar
• Kurosky SK, Davis KL, Galindo CM. Effect of combination vaccines on hepatitis B vaccine compliance in children in the United States. Pediatr Infect Dis J. 2017;36(7):e189–e96.
   PubMed Web of Science ®Google Scholar
• Breton MC, Huang L, Snedecor SJ, et al. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada. Can J Public Health. 2020;111(2):182–192.
   PubMed Web of Science ®Google Scholar
• Balmer P, Burman C, Serra L, et al. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118–1130.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134(3):556–566.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2017 [Internet]. 2017 [cited 2020 Jul 2]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2015 [Internet]. 2015 [cited 2020 Jul 2]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2015.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2016 [Internet]. 2016 [cited 2020 Jul 2]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf
   Google Scholar
• Vesikari T, Ostergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc. 2016;5(2):152–160.
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang LM, Dubey A, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin. 2011;7(2):239–247.
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Kolhe D, et al. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J. 2015;34(11):1236–1243.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• Nimenrix (meningococcal group A, C, W-135 and Y conjugate vaccine). Summary of Product Characteristics. Pfizer Ltd: Sandwich, UK; 2019.
   Google Scholar
• Rivera L, Schwarz TF, Kim KH, et al. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: a phase III, randomized study. Vaccine. 2018;36(31):4750–4758.
   PubMed Web of Science ®Google Scholar
• Quiambao BP, Bavdekar A, Dubey AP, et al. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents. Hum Vaccin Immunother. 2017;13(3):636–644.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–2131.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–327.
   PubMed Web of Science ®Google Scholar
• McMillan M, Walters L, Sullivan T, et al. Impact of meningococcal B (4CMenB) vaccine on pharyngeal Neisseria meningitidis carriage density and persistence in adolescents. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa610. [Epub ahead of print].
   Google Scholar
• Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost-effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725–g5725.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Christensen H, Agnew E, et al. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study [Internet]. Belgian Healthcare Knowledge Centre; 2014 [cited 2020 Jul 2]. Available from: https://kce.fgov.be/sites/default/files/atoms/files/KCE_231S_Meningococcal%20disease_Supplement_1.pdf
   Google Scholar
• Lecocq H, Parent Du Chatelet I, Taha MK, et al. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19):2240–2250.
   PubMed Web of Science ®Google Scholar
• Boccalini S, Bechini A, Sartor G, et al. [Health Technology Assessment of meningococcal B vaccine (Trumenba®) in adolescent in Italy]. J Prev Med Hyg. 2019;60(3 suppl 2):E1–E94.
   PubMedGoogle Scholar
• Vesikari T, Ostergaard L, Beeeslaar J, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019;37(12):1710–1719.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Nimenrix®: EPAR - product information [Internet]. 2020 March 3 [cited 2020 Jul 6]. Available from: https://www.ema.europa.eu/en/documents/variation-report/nimenrix-h-c-2226-ii-0096-epar-assessment-report-variation_en.pdf
   Google Scholar
• Borja-Tabora CFC, Peyrani P, Webber C, et al. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infect Dis. 2020;20(1):426.
   PubMed Web of Science ®Google Scholar
• Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013;13:116.
   PubMed Web of Science ®Google Scholar
• Burman C, Serra L, Nuttens C, et al. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother. 2019;15(2):459–469.
   PubMed Web of Science ®Google Scholar
• MENHIBRIX® (Hib-MenCY-TT). Full Prescribing Information [package insert]. Rixensart, Belgium: GlaxoSmithKline; 2013.
   Google Scholar
• Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–585.
   PubMed Web of Science ®Google Scholar
• Stefanelli P, Miglietta A, Pezzotti P, et al. Increased incidence of invasive meningococcal disease of serogroup C/clonal complex 11, Tuscany, Italy, 2015 to 2016. Euro Surveill. 2016;21(12). DOI:10.2807/1560-7917.ES.2016.21.12.30176
   PubMedGoogle Scholar
• Knol MJ, Ruijs WL, Antonise-Kamp L, et al. Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Euro Surveill. 2018;23(16). DOI:10.2807/1560-7917
   PubMedGoogle Scholar
• Villena R, Valenzuela MT, Bastias M, et al. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine. 2019;37(46):6915–6921.
   PubMed Web of Science ®Google Scholar
• Australian Government Department of Health. Invasive meningococcal disease national surveillance report with a focus on menW [Internet]. 2018 [cited 2020 Jul 2]. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/1Jan-31Mar2018-Consol-Invasive-Men-W.pdf
   Google Scholar
• Presa J, Findlow J, Vojicic J, et al. Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review. Infect Dis Ther. 2019;8(3):307–333.
   PubMed Web of Science ®Google Scholar
• Public Health England. Meningococcal ACWY conjugate vaccination (MenACWY) [Internet]. 2015 [cited 2020 Jul 2]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/437901/150622_ACWY_bipartite_letter.pdf
   Google Scholar
• Signorelli C, Guerra R, Siliquini R, et al. Italy’s response to vaccine hesitancy: an innovative and cost effective National Immunization Plan based on scientific evidence. Vaccine. 2017;35(33):4057–4059.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Revised recommendations of the advisory committee on immunization practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR Wkly. 2007;56(31):794–795.
   PubMedGoogle Scholar
• Rand CM, Goldstein NPN. Patterns of primary care physician visits for US adolescents in 2014: implications for vaccination. Acad Pediatr. 2018;18(2s):S72–S78.
   PubMedGoogle Scholar
• Nolan T, Santolaya ME, de Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37(9):1209–1218.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ostergaard L, Beeslaar J, et al. Antibody persistence up to 26 months after booster dosing in adolescents 4 years following a 2- and 3-dose primary vaccination series of Menb-FHbp. Paper presented at: European Society for Paediatric Infectious Diseases; 2019 May 6-11; Llubjiana, Slovenia.
   Google Scholar
• Gallagher KE, Kadokura E, Eckert LO, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review. BMC Public Health. 2016;16:172.
   PubMed Web of Science ®Google Scholar
• Khan F, Swerdlow DL, York L, et al. 2455. Is category B working? Uptake patterns of meningococcal group B vaccine among US adolescents and young adults. Open Forum Infect Dis. 2018 Nov;5(Suppl 1):S735.
   Google Scholar
• Watkins E, Feemster K. 2460. Factors associated with uptake of meningococcus B vaccination after an ACIP category B recommendation. Open Forum Infect Dis. 2018;5(suppl 1):S737.
   Google Scholar
• Huang L, Goren A, Lee LK, et al. Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations. Hum Vaccin Immunother. 2020;16(4):933–944.
   PubMed Web of Science ®Google Scholar
• Basta NE, Becker AB, Li Q, et al. Parental awareness of meningococcal B vaccines and willingness to vaccinate their teens. Vaccine. 2019;37(4):670–676.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Dempsey A, Galitsky A, et al. Parental awareness and utilization of meningococcal serogroup B vaccines in the United States. BMC Public Health. 2020;20(1):1109.
   PubMed Web of Science ®Google Scholar
• Kempe A, Allison MA, MacNeil JR, et al. Adoption of serogroup B meningococcal vaccine recommendations. Pediatrics. 2018;142(3):e20180344.
   PubMed Web of Science ®Google Scholar
• Kempe A, Allison MA, MacNeil JR, et al. Knowledge and attitudes regarding category B ACIP recommendations among primary care providers for children. Acad Pediatr. 2018;18(7):763–768.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;31(12):1569–1575.
   PubMed Web of Science ®Google Scholar
• Harris SL, Tan C, Andrew L, et al. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. Vaccine. 2018;36(45):6867–6874.
   PubMed Web of Science ®Google Scholar
• Knol M, Hahne S, Ruijis W, et al. Invasive meningococcal serogroup W disease in the Netherlands after a MenACWY vaccination campaign. Poster presented at: European Society for Paediatric Infectious Diseases 2020 Oct 26-29; Virtual meeting
   Google Scholar
• Mbaeyi S, Pondo T, Blain A, et al. Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. JAMA Pediatr. 2020;174(9):843–851.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):e20162193.
   PubMed Web of Science ®Google Scholar